Research programme: interleukin-6 inhibitors - Y's Therapeutics

Drug Profile

Research programme: interleukin-6 inhibitors - Y's Therapeutics

Alternative Names: Anfil6; YSIL-6; YSIL6-O-RA; YSIL6-T-PS

Latest Information Update: 28 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ys Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Rheumatoid arthritis
  • Discontinued Crohn's disease; Psoriasis

Most Recent Events

  • 28 Feb 2011 Early research is ongoing in Japan
  • 28 Jul 2004 Discontinued - Preclinical for Crohn's disease in Japan (PO)
  • 27 Jul 2004 Y's Therapeutics has filed an application to begin phase II trials with the Ministry of Health in Germany for Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top